Options positioning on Merck & Co. just flashed its most bearish read in three weeks. The put/call ratio hit 0.8468 on August 21 — 3.2 standard deviations above the 20-day mean of 0.763. That's the loudest options signal on the stock since the analyst re-rating wave crested.
The timing matters. MRK has run 15% in a month. It now trades at $150.66, above the mean analyst consensus target of $147.77. The stock blew through that level earlier this week. Options traders are now paying elevated premiums for downside protection.
The PCR hasn't been this elevated since late July, when it briefly touched 0.86. The 52-week high is 0.9816. At 0.8468, the current reading isn't a record — but the velocity is notable. The ratio sat in a narrow 0.73–0.78 band for most of the past month. The jump to 0.85 in a single session is the outlier.
Put buying at this level suggests some participants are hedging recent gains rather than making fresh directional bets against the stock. Either way, the signal is clear: sentiment in the options market has cooled.
The analyst picture adds texture. RBC downgraded to Sector Perform on August 20, raising its target modestly to $150 — essentially where the stock sits now. That's a cautious call framed as a valuation check after the rally.
The bullish camp remains loud. Goldman Sachs raised its target to $160. UBS sits at $175. Morgan Stanley — which reversed from Equal-Weight to Overweight in a single dramatic move — targets $179. The mean consensus sits at $147.77, already below the current price.
The spread between the outlier targets and the consensus is unusually wide. That gap reflects genuine disagreement about how far Keytruda-driven growth can carry the stock above $150.
Insider selling has continued. The General Counsel sold $10.7 million worth of shares on August 12. An Executive Vice President sold $1.35 million on August 13. The 90-day net insider position, in shares, is modestly positive — but the recent pattern in dollar terms skews firmly toward selling into strength.
The borrow market remains trivially loose. Availability is effectively unconstrained, with 2.28 billion shares available to borrow. SI is just 1.14% of free float. The short angle adds nothing to the story here.
Watch: Whether the PCR normalises back toward 0.76 — or extends toward the 52-week high of 0.98 — will say a lot about how options traders view the stock's risk/reward into Q3 earnings.
See the live data behind this article on ORTEX.
Open MRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
